AbbVie’s RINVOQ shows promise in Vitiligo Phase 3 trials
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Basketball legend, entrepreneur, and entertainer Shaquille O’Neal partners with Lilly to encourage Americans to recognize the signs of obstructive sleep apnea and talk to their
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
AI-powered cardiometabolic wellness platform for India’s workforce
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Subscribe To Our Newsletter & Stay Updated